Dose-Escalation, Single-Center, Open-label Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Adeno-associated Virus(AAV) Gene Therapy Product IPS101A in Parkinson's Disease Patients With Hoehn-Yahr Stage 4-5, Diagnosed in More Than 10 Years and Uncontrolled by All Available Monotherapy or Combination Therapy
Latest Information Update: 05 Feb 2026
At a glance
- Drugs IPS 101A (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Innopeutics
Most Recent Events
- 05 Feb 2026 New trial record